A recent clinical trial, published in The Lancet, involving a 6-week course of a combination of 3 direct-acting oral drugs was found to cure 38 of 40 individuals with hepatitis C virus infection (HCV).
The researchers had found that a 6-week course of therapy is actually half the length of time typically reported to achieve a similar, successful cure rate using only2 direct-acting oral HCV drugs.
For the clinical trial, the first group of 20 volunteers were administered a 6-week course of the newly licensed drug sofosbuvir (Sovaldi) coupled with 2 additional direct-acting oral therapies, ledipasvir and GS-9669 – an experimental drug. The second volunteer group also comprised of 20 individuals had received another 6-week course of sofosbuvir, ledipasvir, and a different experimental drug, GS-9451
. - See more at: http://www.hcplive.com/articles/Six-week-Oral-Drug-Trial-Produces-High-Hepatitis-C-Cure-Rates#sthash.eftwAdC7.dpuf
No comments:
Post a Comment